What the Study Found (In Plain English)
Published in Blood (2023), this phase iii randomized trial evaluating 101 human participants investigated: We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria. Key clinical takeaway: No participant had hydroxyurea therapy stopped for myelosuppression. For children with SCA in low-income settings without access to regular...
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Blood, 2023-02-23; N = 101; Rigor 88/100): No participant had hydroxyurea therapy stopped for myelosuppression. For children with SCA in low-income settings without access to regular blood transfusion therapy, initial low-dose hydroxyurea is a minimum known efficacious dose for secondary stroke prevention.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.